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OBJECTIVES: Surgery remains the cornerstone treatment modality for gastric cancer, the fifth most common
type of tumor in Brazil. The aim of this study was to analyze the surgical treatment outcomes of patients with
gastric cancer who were referred to a high-volume university hospital.
METHODS: We reviewed all consecutive patients who underwent any surgical procedure due to gastric cancer
from a prospectively collected database. Clinicopathological characteristics, surgical and survival outcomes were
evaluated, with emphasis on patients treated with curative intent.
RESULTS: From 2008 to 2017, 934 patients with gastric tumors underwent surgical procedures in our center.
Gastric adenocarcinoma accounted for the majority of cases. Of the 875 patients with gastric adenocarcinoma,
resection with curative intent was performed in 63.5%, and palliative treatment was performed in 22.4%. The
postoperative surgical mortality rate for resected cases was 5.3% and was related to D1 lymphadenectomy and
the presence of comorbidities. Analysis of patients treated with curative intent showed that resection extent, pT
category, pN category and final pTNM stage were related to disease-free survival (DFS) and overall survival (OS).
The DFS rates for D1 and D2 lymphadenectomy were similar, but D2 lymphadenectomy significantly improved
the OS rate. Additionally, clinical factors and the presence of comorbidities had influence on the OS.
CONCLUSIONS: TNM stage and the type of lymphadenectomy were independent factors related to prognosis.
Early diagnosis should be sought to offer the optimal surgical approach in patients with less-advanced disease.
KEYWORDS: Gastric Cancer; Gastrectomy; Operative Surgical Procedures.
’ INTRODUCTION
Gastric cancer (GC) is the fifth most common cancer
worldwide. Approximately one million (952,000) new cases of
GC occurred worldwide in 2012 (1). In Brazil, it is estimated
12,920 new cases of stomach cancer occurred in men and
7,600 occurred in women in the biennium 2016 2017 (2).
Adenocarcinoma is the most frequent histological type of GC,
accounting for more than 95% of tumors. Other histological
types are gastrointestinal stromal tumor (GIST), leiomyoma,
lymphoma, and neuroendocrine tumor (3).
Surgery remains the main curative option of GC.
Gastrectomy with D2 lymphadenectomy is considered the
standard surgical treatment for locally advanced GC; this
modality is characterized by tumor resection with adequate
margins along with removal of the lymph nodes at the origin
of the main gastric vessels. A more limited D1 lymphade-
nectomy may be indicated for frail patients with multiple
comorbidities. Furthermore, endoscopic treatment may be an
option for early tumors with a low risk of lymph node
metastasis (4).
Unfortunately, not all patients are candidates for resection
with curative intent. A substantial number of patients
undergo noncurative procedures to palliate symptoms such
as obstruction and/or bleeding. Moreover, diagnostic surgi-
cal procedures may be employed to assess peritoneal
dissemination and define the purpose of chemotherapy as
either neoadjuvant or palliative (4).
The aim of this study was to analyze the characteristics
and outcomes of patients with gastric tumors who were
referred to surgical treatment at a high-volume university
hospital. Clinicopathological characteristics, surgical and
survival outcome were evaluated with emphasis on patients
treated with curative intent.
’ METHODS
We reviewed all consecutive patients who underwent
any surgical procedure due to GC from 2008 to 2017 atDOI: 10.6061/clinics/2018/e543s
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Cancer Institute, University of Sao Paulo Medical School.
The data were prospectively collected and entered into a
clinical database. Patients with tumors not originating in the
stomach or who underwent gastric surgical procedures
related to benign conditions such as peptic ulcer or
gastrostomy were excluded from the analysis.
Patients were staged preoperatively through abdominal
and pelvic computed tomography, upper digestive endo-
scopy and laboratory tests. The intent of surgery and surgical
technique followed the recommendations of the Japanese
Gastric Cancer Association guidelines (4). Patients who had
previously undergone diagnostic or endoscopic procedures
but subsequently underwent resection were included in the
resection group. The extent of the gastric resection (total 
subtotal) was based on the location of the tumor in order to
obtain a tumor-free proximal margin (5). Resection was
defined as R0, R1 or R2 according to the amount of residual
tumor (no residual tumor, microscopic or macroscopic,
respectively). The extent of nodal dissection (D1 or D2
lymphadenectomy) was defined according to the lymph
node chains removed. TNM staging was performed accord-
ing to the 7th edition (6).
All surgeries were performed by surgeons with extensive
experience in the surgical management of GC. Some
emergency procedures were performed by other gastroin-
testinal surgeons at the hospital. Surgical residents played an
active role during most procedures. Complex cases were
discussed in the weekly multidisciplinary meeting.
Clinical characteristics, including American Society of Anes-
thesiologists (ASA) classification (7), Charlson–Deyo comorbid-
ity index (CCI) (8), and laboratory test results, were evaluated.
The CCI was evaluated without the inclusion of age and GC
neoplasm as a comorbidity.
Surgical complications were graded according to the
ClavienDindo classification (9). Major complications were
considered Clavien IIIV. The hospitalization period and the
number of retrieved lymph nodes were evaluated. Surgical
mortality was considered when death occurred within the
first 30 days after surgery or during the hospital stay after the
procedure.
Postoperative follow-up was performed on a quarterly
basis in the first year after surgery and every six months in
the following years. Follow-up studies for relapse detection
were performed based on the presence of symptoms.
Absence from medical appointments for more than 12
months was considered loss to follow-up.
The study is part of a larger project, ‘‘Banco de dados de
pacientes do Servic¸o de Cirurgia do Aparelho Digestivo do
ICESP-HCFMUSP’’, which was approved by the hospital
ethics committee (NP993/16) and registered in the ‘‘Plata-
forma Brasil’’ (CAAE: 2915516.2.0000.0065).
Statistical analysis
The descriptive statistics included frequencies with per-
centages for nominal variables and means for continuous
variables. To evaluate the differences between the variables,
chi-square tests were used for categorical data; t-tests, for
continuous data. Disease-free survival (DFS) and overall
survival (OS) were estimated using the Kaplan–Meier
method, and differences in survival were compared using
the log-rank test. To determine factors associated with DFS
and OS, we used univariate and multivariate Cox propor-
tional hazards regression models. Variables significant in the
univariate analysis were included as covariables in the
multivariable analysis to determine which variables inde-
pendently affected prognosis. Survival time was calculated
from the date of surgery until the date of death/recurrence.
Surviving patients were censored at the date of last contact.
All tests were two-sided, and statistical significance was
defined as po0.05. Analyses were performed using SPSS
software, version 18.0 (SPSS Inc, Chicago, IL).
’ RESULTS
A total of 934 patients were surgically treated for primary
gastric tumors between 2008 and 2017 in our institution.
Gastric adenocarcinoma was diagnosed in 875 patients
(93.7%). Nonadenocarcinoma primary gastric tumors, inclu-
ding GIST (n=31, 3.3%), neuroendocrine tumor (n=10, 1.1%)
and lymphoma (n=8, 0.9%), were detected in 59 patients
(6.3%). Ten patients (1.1%) presented benign tumors, such as
leiomyoma, lipoma and schwannoma. Nonadenocarcinoma
tumors were not included in further analyses.
Clinical and surgical characteristics of the remain-
ing 875 gastric adenocarcinoma patients are shown in
Table 1. The mean age at initial diagnosis was 63.5 years
(range 23–95 years), and 81 patients (9.3%) were older
than 80. The proportion of male patients was higher than
female patients, with a male female ratio of 1.7, and the
mean body mass index (BMI) of the cohort was 23.7 kg/m2.
The predominant CCI was 0-1, and the ASA preoperative
risk classification was I/II for the majority of the patients
(72.9%).
Table 1 - Clinical and surgical characteristics of patients with
gastric adenocarcinoma. All patients (n=875).
Variables n %
Age (years)
Mean (range) 63.5 (23-95)
Sex
Male 550 62.9
Female 325 37.1
Charlson–Deyo Comorbidity Index (CCI)*
01 770 88
41 83 9.5
American Society of Anesthesiologists (ASA)
Classification
I/II 638 72.9
III/IV 237 27.1
Type of Surgery
Curative intent (D1 or D2) 556 63.5
Palliative 196 22.4
Diagnostic 68 7.8
Endoscopic 42 4.8
Cytoreduction/salvage surgery 13 1.5
Tumor Location
Upper/middle 195 22.3
Lower 472 53.9
Entire 15 1.7
Anastomosis 41 4.7
Not available 152 17.4
TNM Stage
I 229 26.2
II 136 15.5
III 282 32.2
IV 228 26.1
* Some cases were not assessed for this status due to the absence of the
relevant information in the original medical report.
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Of these patients, 63.5% were treated with curative intent,
while 22.4% underwent palliative surgery. Regarding tumor
location, 53.9% of the lesions were located in the distal
stomach. Among the patients who underwent resection, the
residual tumor category was R0 in 68.9%, R1 in 1.4%, and R2
in 29.7%. Regarding the UICC TNM stage classification,
cTNM stage III was the most frequent (32.2% of patients).
Survival analysis – Gastric adenocarcinoma patients
All adenocarcinoma patients were included in the first
survival analysis. The mean follow-up duration was 28
months (range 0-99 months). During follow-up, 45.2% of the
patients had disease recurrence, and 360 died. A total of 110
(12.6%) patients were lost during follow-up. The DFS and OS
rates for the entire cohort were 54.8% and 58.9%, respec-
tively. Figure 1 shows the OS rate for the patients according
to cTNM stage and treatment intent. For the different stages,
the OS rate was 87.3% for stage I, 76.5% for stage II, 52.8% for
stage III, and 27.2% for stage IV disease. Patients who
underwent endoscopic treatment, followed by patients who
underwent resection with curative intent, had higher
survival rates than patients who underwent other treatments
(90.5% and 71.2%, respectively). Patients who received
palliative (79.7% were staged as IV) or diagnostic procedures
(77.9% were staged as IV) had survival rates of 28.2%
(median OS= 8 months, 95% CI 6.16–9.84 months) and 27.9%
(median OS= 7 months, 95% CI 5.60–8.40 months), respec-
tively, with no patients alive at the 5-year follow-up.
Clinicopathological features – Gastrectomy with
curative intent group
To better assess the pathological characteristics and
survival outcomes of patients with GC treated at our
institution, we further analyzed only the 509 patients with
gastric adenocarcinoma who underwent surgical resection
with curative intent. Patients with gastric remnant tumors
were not included. The clinicopathological characteristics of
these patients are shown in Table 2.
The mean age was 62.9 years, and male patients accounted
for 304 cases (59.7%). The mean BMI at the time of surgery was
24.6 kg/m2 (range 13 57), and the mean albumin and
hemoglobin levels were 4.0 mg/dL and 12.5 g/dL, respectively.
Neoadjuvant therapy was performed in 64 (12.6%) patients.
The main tumor location was the lower third of the
stomach, and subtotal gastrectomy with D2 lymphadenect-
omy was the most common procedure performed. Forty-five
(8.8%) surgeries were performed laparoscopically, and 22
(4.3%) were robotic surgeries. Total gastrectomy was
performed more frequently for pT3/T4 tumors than for
pT1/T2 tumors (67.7% vs. 33%, p=0.008).
Regarding the pT category, subserosal layer invasion
occurred in 31.6% of the patients. Lymph node metastases
were present in 55.2% of the cases, with a mean of 4.9 (range
0 67) positive lymph nodes per patient. The mean number
of lymph nodes retrieved in the surgical specimens over all
patients was 39.5. Regarding the type of lymphadenectomy,
a mean of 41.8 lymph nodes were obtained in D2 dissection
and 27.7 in D1 dissection (po0.001). Regarding the TNM
classification, pTNM stage III was the most frequent stage
(42% of cases).
The median length of hospital stay was 9 days (4–73 days).
Minor complications (grades I and II) occurred in 94 patients
(18.5%), while major complications happened in 44 (8.6%)
patients. The postoperative mortality rate was 5.3% (27 patients).
Mortality was higher for those who underwent D1 lympha-
denectomy (n=13, 15.3%) than for those receiving D2
lymphadenectomy (n=13, 3.3%) (po0.001). The main causes
of death were pneumonia (7 of 20 patients), followed by
duodenal stump fistula (5 of 15 patients), with surgical
mortality rates of 35% and 33.3%, respectively. Complica-
tions were more frequent in elderly patients (470 years=
20% vs. o70 years=11%, po0.001), patients with higher CCI
(0 1= 13.5% vs. 41= 17.3%, p=0.017) and patients with an
higher ASA classification (I/II= 11.2% vs. III/IV= 24.1%,
po0.001).
Postoperative adjuvant chemotherapy and chemoradio-
therapy were administered to 117 (23%) and 118 (23.2%)
patients, respectively. During the follow-up period, the DFS
and OS rates for the cohort treated with curative intent
resection was 76.8% and 72.3%, respectively. Of the 110
patients with recurrence, the most frequent sites of recur-
rence were local/regional lymph nodes (67 patients, 60.9%),
the peritoneum (43 patients, 39.1%) and distant sites
(45 patients, 40.9%), with some patients presenting more
than one site of recurrence. The main sites of distant
metastasis were the liver (26 patients), lung (10 patients),
bones (5 patients) and ovary (4 patients).
Figure 1 - Survival curves for gastric adenocarcinoma patients according to cTNM stage and surgical intent.
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Survival analysis – Gastrectomy with curative intent
group
Survival analysis showed that extent of surgery (total
gastrectomy), greater depth of tumor invasion (pT status),
higher frequency of metastatic lymph nodes (pN status) and
more advanced pTNM stage had a significant negative
impact on DFS and OS (Figures 2, 3 and 4). The DFS rates for
D1 and D2 lymphadenectomy were similar (p=0.736), but
D2 lymphadenectomy significantly improved the OS rate
(po0.001).
In the DFS analysis, the log-rank test for pT category
revealed a statistically significant difference between stages
T1 and T3 (po0.001), T1 and T4 (po0.001), T2 and T3
(po0.001) and T3 and T4 (p=0.001). However, no significant
difference was found between stages T1 and T2 (p=0.801). In
addition, there were statistically significant differences across
the pN categories: between stages N0 and N1/N2/N3
(po0.001 for all), N1 and N3 (po0.001), and N2 and N3
(p=0.04). However, no significant difference was noted
between stages N1 and N2 (p=0.176).
Regarding OS, the log-rank test for pT category revealed
statistically significant differences between stages T1 and T3
(po0.001), T1 and T4 (po0.001), T2 and T4 (p=0.001) and T3
and T4 (p=0.024). However, no significant difference was
found between stages T1 and T2 (p=0.244) or T2 and T3
(p=0.062). Across pN category, statistically significant differ-
ences were observed between stages N0 and N2/N3
(po0.001 for both), N1 and N2 (p=0.030), and N1 and N3
(p=0.007). However, no significant difference was noted
between stages N0 and N1 (p=0.085) or N2 and N3 stage
(p=0.563). Although no significant difference was noted
between some pT and pN categories, the cumulative survival
curves for patients with different stages did not intersect
(Figure 3).
The results of the multivariate analysis are shown in
Table 3. Worse DFS was associated with type of gastrectomy,
depth of invasion (pT) and lymph node metastasis
(pN). Regarding OS, the multivariate analysis identified
advanced age, ASA classifications III and IV, CCI 41, D1
lymphadenectomy, diffuse/mixed Lauren type, pT3/T4
and pN1/N2/N3 stage as independent predictors of poor
prognosis.
’ DISCUSSION
In the present study, we reported a broad view of GC
surgical treatment based on a 10-year experience in a high-
volume center. Gastric adenocarcinoma accounted for the
vast majority of the cases. Resection with curative intent was
performed in 63.5% of the patients. Resection extent, pT
category, pN category and final pTNM stage were related to
DFS and OS. OS was also influenced by the clinical factors
and comorbidities of the patients.
Initial analysis of clinical staging can provide insight into
the state in which patients eventually present at a reference
center for treatment. A quarter of the cases were already
stage IV, and the survival rates of patients not treated with
curative intent are clearly lower than those treated with
curative intent. Regarding the type of surgical procedure,
endoscopic resection accounted for only a small percentage,
and a substantial number of palliative procedures were
performed. These findings highlight the need for impro-
ving public health policy to achieve earlier diagnosis of
GC. Countries with a more active policy of screening
and testing symptomatic patients have an incidence rate of
early tumors of higher than 50% (10). Even though we expect
to improve the rate of early diagnosis in the future, we
were encouraged and surprised by the frequency of 34% for
stage I classification in resected patients (11). Recent series
from referral centers in Chile, China and the United States
reported stage I frequencies of 19.3%, 28% and 50%, res-
pectively (12,13).
Surgical mortality rate of resected patients was 5.3%,
reflecting the high complexity of these procedures. The
main causes of death were pneumonia and duodenal
stump fistula, which was previously described as the most
lethal surgical complication following gastrectomy (14).
Complications and mortality were related to older patients
with comorbidities who underwent D1 lymphadenectomy.
Table 2 - Clinicopathological characteristics of gastric
adenocarcinoma patients after curative intent resection (n=509).
Variables n %
Age (years)
Mean (range) 62.9 (23 - 95)
Sex
Male 304 59.7
Female 205 40.3
Charlson–Deyo Comorbidity Index (CCI)*
0 1 444 87.2
41 52 10.2
American Society of Anesthesiologists (ASA)
Classification
I/II 401 78.8
III/IV 108 21.2
Type of Resection
Subtotal gastrectomy 330 64.8
Total gastrectomy 179 35.2
Lymphadenectomy
D2 425 83.5
D1 84 16.5
Tumor Location
Upper 38 7.5
Middle 105 20.6
Lower 318 62.5
Entire 10 2.0
not available 38 7.5
Tumor Size (cm)
Mean 4.85
Lauren Type*
Intestinal 263 51.7
Diffuse/mixed 223 43.8
Undetermined 20 3.9
pT Status
pT1/is 146 28.7
pT2 62 12.2
pT3 161 31.6
pT4 140 27.5
Harvested Lymph Nodes
Mean (SD) 39.5
pN Status
pN0 228 44.8
pN1 68 13.4
pN2 89 17.5
pN3 124 24.4
TNM Stage
I 173 34,0
II 114 22.4
III 214 42.0
IV 8 1.6
* Some cases were not assessed for this status due to the absence of the
relevant information in the original medical report.
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Figure 3 - Survival curves according to depth of invasion and lymph node status for patients who underwent curative resection.
Figure 2 - Survival curves according to the type of surgery and lymphadenectomy for patients who underwent curative resection.
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Importantly, our criterion for performing D1 dissection is
precisely restricted to patients with a high surgical risk. This
association demonstrates the appropriate indication for a
more limited procedure in high-risk patients. When we
consider only D2 dissection, mortality drops to 3.3%, similar
to that observed in other Western series (12,15-17). In
addition to the type of lymphadenectomy, in the present
study total gastrectomy was associated with a poorer
prognosis compared to subtotal resection. This association
may be related to the higher risk for serious postoperative
complications after total gastrectomy and the different
molecular subtypes of GC (18,19).
The mean number of harvested lymph nodes is used
globally to compare and evaluate surgical quality. The mean
number of lymph nodes obtained in D2 lymphadenectomy
was 41.8, which greatly exceeds the minimum number of
16 recommended for an adequate TNM staging (6) and the
minimum number of 25 recommended by the Brazilian
Consensus Guidelines (5) to consider a D2 lymphadenect-
omy adequate. Even D1 cases with a mean of 27.7 lymph
nodes harvested meet the requirements for an adequate
lymph node dissection.
The oncological benefits of D2 dissection have been widely
described in the literature (20,21). Even though, in our series,
the DFS rates for D1 and D2 lymphadenectomy were similar
(p=0.736), D2 lymphadenectomy significantly improved the
OS. However, patients with poorer clinical conditions exhibit
a limited expected survival time; therefore, they may not
have time to benefit from D2 lymph node dissection. The
balance between the patient
́
s comorbidities and the choice
of lymphadenectomy in each individual case is a challenge
for surgeons.
Figure 4 - Survival curves according to pTNM stage for patients who underwent curative resection.
Table 3 - Univariate and multivariate analysis of disease-free survival and overall survival.
Disease-free Survival Univariate Multivariate
Variables* Hazard Ratio 95% CI p Hazard Ratio 95% CI p
Age 0-69 vs. X70 years 0.69 0.44-1.07 0.095 — — —
Female vs. Male 1.07 0.73-1.58 0.710 — — —
ASA I/II vs. III/IV 0.91 0.54-1.53 0.733 — — —
Charlson 0-1 vs. Charlson 41 0.87 0.44-1.72 0.693 — — —
Subtotal vs. Total gastrectomy 2.16 1.48-3.14 o0.001 1.83 1.26-2.67 0.002
D2 vs. D1 lymphadenectomy 1.10 0.64-1.89 0.737 — — —
Intestinal vs. Diffuse/mixed 1.91 1.30-2.79 0.001 1.44 0.98-2.17 0.062
pT1/pT2 vs. pT3/pT4 10.03 5.07-19.85 o0.001 4.6 2.20-9.68 o0.001
pN0 vs. pN1/2/3 8.48 4.65-15.46 o0.001 3.68 1.99-7.08 o0.001
Overall Survival Univariate Multivariate
Variables* Hazard Ratio 95% CI p Hazard Ratio 95% CI p
Age 0-69 vs X70 years 1.50 1.07-2.11 0.019 1.44 1.01-2.06 0.044
Female vs. Male 1.18 0.84-1.66 0.352 — — —
ASA I/II vs. III/IV 2.08 1.44-3.01 o0.001 1.68 1.10-2.56 0.016
Charlson 0-1 vs. Charlson 41 1.54 0.94-2.53 0.089 — — —
Subtotal vs. Total gastrectomy 1.58 1.13-2.21 0.008 1.61 1.14-2.25 0.006
D2 vs. D1 lymphadenectomy 2.19 1.48-3.24 o0.001 1.99 1.26-3.13 0.003
Intestinal vs. Diffuse/mixed 1.49 1.06-2.07 0.002 1.45 1.03-2.05 0.034
pT1/pT2 vs. pT3/pT4 2.92 1.96-4.36 o0.001 1.91 1.18-3.11 0.009
pN0 vs. pN1/2/3 3.03 2.06-4.47 o0.001 2.04 1.27-3.29 0.002
* The first variable represents the reference category.
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Stage II/III/IV patients, the target population for multi-
modal treatment according to the hospital protocol, accounted
for 66% of the patients. However, only 46% of cases received
any type of adjuvant therapy. Referral of patients to the
medical oncology department at the hospital is fast and
straightforward. The lack of provision of adjuvant treatment
was probably due to the poor clinical performance of patients.
Furthermore, the occurrence of tumors with low lymph node
involvement in patients with well-performed surgical resec-
tion may have discouraged adjuvant therapy.
As expected, the greater the tumor invasion, the poorer
was the prognosis. The DFS and OS significantly decreased
from stage pT3 upward. Patients with tumors staged pT3
or pT4 had significantly poorer prognosis than those with
tumors staged pT2. Similarly, the survival rates were
markedly decreased for patients with increased numbers of
metastatic lymph nodes. Patients with one or more positive
lymph nodes had a statistically significantly poorer DFS than
patients with negative nodes. Furthermore, OS was sig-
nificantly poorer in patients with more than three metastatic
lymph nodes (stage pN2 or higher).
Our survival analysis demonstrated a very sharp separa-
tion of the DFS curves when stratified by the pTNM stage.
However, the same linearity was not seen for the OS curves.
This finding can be explained by several reasons. First, many
patients did not complete the recommended 5-year follow-
up and, as recurrence happens first, the DFS curves become
separated earlier. Second, some patients with GC are very
frail and can die of other causes. Therefore, deaths during
follow-up may occur despite TNM staging, thus influencing
only the OS. Furthermore, loss to follow-up occurs more
often after than before the diagnosis of recurrence, because
some patients facing the end phase of the disease tend to
return to their hometowns. Thus, we have information about
recurrence events, but the date of death may be unknown.
Regardless of the underlying factors that influence sur-
vival, our analyses showed that curative gastric resection
with extended lymphadenectomy, along with early detection
of the cancer, markedly contributed to improving survival.
Importantly, despite complete surgical clearance of the pri-
mary tumor (R0 resection), some patients still suffer local or
distant disease recurrence (60.9% and 40.9%, respectively, in
our cohort), possibly due to disseminated micrometastases
present at the time of surgery (22).
The current study has some limitations. As the objective of
the study was to give a broad view of GC treatment with the
description of the entire population, some variables and
subgroups were not deeply analyzed. We did not consider
the type of adjuvant therapy, which may influence survival
by the administration of different regimens with different
schedules. In addition, multivariate analyses were performed
only with patients treated with curative intent, and stage
subgroups such as T1a/T1b, T4a/T4b and N3 categories
were presented as a single category (pT1, pT4 and pN3), and
were not considered separately in the survival analyses. The
surgical morbimortality analysis was limited to patients
treated with curative resection. Last, some included patients
have not yet reached the follow-up time of 5 years.
To our knowledge, this series is one of the largest to report
the analysis of the clinicopathological characteristics and
survival of patients with GC in Brazil. All patients were
treated in a referral oncology hospital by surgeons dedicated
to GC surgery. This inclusion criterion improves the accu-
racy and homogeneity of the perioperative clinical data.
In addition, survival outcome is based on a cohort of patients
with a high number of examined lymph nodes, which
minimizes the risk for understaging. Furthermore, follow-up
was available for 765 (87.4%) of the 875 patients. Through
the inclusion of all patients who underwent any surgical
procedure, a broad view of current GC surgical management
can be obtained while minimizing selection bias.
In conclusion, these results demonstrate the relevance
of awareness of surgical outcomes, survival and factors
associated with prognosis in clinical settings. These data
convey prognostic information that assists in the selection of
different surgical modalities and clarify the surgical risks
involved in the treatment to determine the best therapeutic
strategy for GC patients. Early diagnosis should be sought
since it is evident the relationship between disease stage and
prognosis, in addition to the low survival rates of patients
who cannot be treated with surgery.
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